FY2026 EPS Estimate for Elevance Health Reduced by Analyst

Elevance Health, Inc. (NYSE:ELV - Free Report) - Equities research analysts at Cantor Fitzgerald decreased their FY2026 earnings per share estimates for shares of Elevance Health in a note issued to investors on Wednesday, October 22nd. Cantor Fitzgerald analyst S. James now expects that the company will post earnings of $27.47 per share for the year, down from their previous estimate of $33.72. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share.

Elevance Health (NYSE:ELV - Get Free Report) last released its quarterly earnings results on Tuesday, October 21st. The company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.03 by $1.00. The business had revenue of $50.09 billion during the quarter, compared to analyst estimates of $49.26 billion. Elevance Health had a net margin of 2.84% and a return on equity of 16.17%. The company's quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm posted $8.37 earnings per share.

Other equities research analysts also recently issued reports about the stock. Barclays lowered their target price on shares of Elevance Health from $395.00 to $385.00 and set an "overweight" rating for the company in a research note on Wednesday. Robert W. Baird dropped their target price on Elevance Health from $492.00 to $297.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Wall Street Zen downgraded Elevance Health from a "buy" rating to a "hold" rating in a research note on Friday, July 18th. UBS Group dropped their target price on Elevance Health from $435.00 to $425.00 and set a "buy" rating on the stock in a research note on Friday, September 5th. Finally, Wells Fargo & Company cut their price objective on shares of Elevance Health from $412.00 to $403.00 and set an "overweight" rating on the stock in a report on Wednesday. Twelve analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $397.89.

Elevance Health Price Performance

Shares of ELV opened at $346.36 on Friday. The company has a market cap of $76.97 billion, a price-to-earnings ratio of 14.16, a price-to-earnings-growth ratio of 1.26 and a beta of 0.59. Elevance Health has a twelve month low of $273.71 and a twelve month high of $458.75. The company has a quick ratio of 1.44, a current ratio of 1.56 and a debt-to-equity ratio of 0.71. The company has a 50 day moving average of $326.42 and a two-hundred day moving average of $353.99.

Institutional Investors Weigh In On Elevance Health

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company's stock worth $8,890,419,000 after acquiring an additional 704,790 shares during the period. Sanders Capital LLC raised its stake in shares of Elevance Health by 24.7% during the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company's stock valued at $2,265,773,000 after buying an additional 1,152,440 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of Elevance Health by 9.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 3,675,179 shares of the company's stock valued at $1,429,498,000 after buying an additional 324,399 shares during the last quarter. Norges Bank purchased a new position in shares of Elevance Health during the 2nd quarter valued at about $1,148,379,000. Finally, Orbis Allan Gray Ltd raised its stake in shares of Elevance Health by 31.4% during the 1st quarter. Orbis Allan Gray Ltd now owns 2,849,173 shares of the company's stock valued at $1,239,276,000 after buying an additional 680,228 shares during the last quarter. Hedge funds and other institutional investors own 89.24% of the company's stock.

Insider Buying and Selling

In other news, Director Susan D. Devore bought 1,200 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The shares were purchased at an average price of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the transaction, the director directly owned 3,502 shares in the company, valued at approximately $1,093,149.30. This represents a 52.13% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.29% of the company's stock.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 19th. Shareholders of record on Friday, December 5th will be given a dividend of $1.71 per share. The ex-dividend date of this dividend is Friday, December 5th. This represents a $6.84 dividend on an annualized basis and a yield of 2.0%. Elevance Health's payout ratio is currently 29.11%.

Elevance Health Company Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.